CytoSorbents, a critical care-focused company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses, today announced its CEO, Dr. Phillip Chan, was named as a finalist in the Ernst & Young Entrepreneur Of The Year® 2012 program, which recognizes entrepreneurs with demonstrated success in areas such as innovation, financial performance, and personal commitment.
Dr. Chan was selected by an independent judging panel comprised of previous winners, CEOs, private capital investors, and other regional business leaders.
Since his appointment as CytoSorbents CEO and president in 2009, Dr. Chan has taken initiatives to build the company into an emerging pioneer of advanced blood purification technologies, and is currently guiding the company through the transition from a development-stage company into an early commercialization stage company through the approval and early sales of its flagship product, CytoSorb®, in the EU.
As a board-certified internal medicine physician, Dr. Chan previously led healthcare and life science investments as Partner for the $80M NJTC Venture Fund and co-founded Andrew Technologies, a venture-backed medical device company.
Dr. Chan completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center; received his MD/PhD from Yale University School of Medicine; and received his bachelor of science in cell and molecular biology with honors and distinction from Cornell University.
Awards will be presented at a special gala on June 27, 2012, at the Hyatt New Brunswick.
For more information visit www.cytosorbents.com
Let us hear your thoughts below: